Is Intellia Therapeutics, Inc. (NTLA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.9% / 30% | 28.3% / 30% | 0.6% / 30% | 43.14% / 5% | ✗ NOT HALAL |
| DJIM | 5.9% / 33% | 28.3% / 33% | 0.6% / 33% | 43.14% / 5% | ✗ NOT HALAL |
| MSCI | 11.1% / 33% | 53.4% / 33% | 1.1% / 33% | 43.14% / 5% | ✗ NOT HALAL |
| S&P | 5.9% / 33% | 28.3% / 33% | 0.6% / 33% | 43.14% / 5% | ✗ NOT HALAL |
| FTSE | 11.1% / 33% | 53.4% / 33% | 1.1% / 50% | 43.14% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -428.9% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -53.5% | |
| Return on Assets (ROA) | -27.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$395M |
| Free Cash Flow | -$396M |
| Total Debt | $93M |
| Debt-to-Equity | 13.9 |
| Current Ratio | 5.1 |
| Total Assets | $842M |
Price & Trading
| Last Close | $13.24 |
| 50-Day MA | $13.16 |
| 200-Day MA | $12.71 |
| Avg Volume | 4.8M |
| Beta | 2.0 |
|
52-Week Range
$5.90
| |
About Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Intellia Therapeutics, Inc. (NTLA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Intellia Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Intellia Therapeutics, Inc.'s debt ratio?
Intellia Therapeutics, Inc.'s debt ratio is 5.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.1%.
What are Intellia Therapeutics, Inc.'s key financial metrics?
Intellia Therapeutics, Inc. has a market capitalization of $1.5B, and revenue of $68M. Return on equity stands at -53.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.